274671-76-0

Basic information

• Product Name: 5-bromo-2-(bromomethyl)-1,3-dichlorobenzene
• Synonyms: 5-bromo-2-(bromomethyl)-1,3-dichlorobenzene
• CAS NO: 274671-76-0
• Molecular Weight: 318.823
• Mol File: 274671-76-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 5-bromo-2-(bromomethyl)-1,3-dichlorobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-2-(bromomethyl)-1,3-dichlorobenzene(274671-76-0)
• EPA Substance Registry System: 5-bromo-2-(bromomethyl)-1,3-dichlorobenzene(274671-76-0)

Safety Data

• Hazardous Substances Data: 274671-76-0(Hazardous Substances Data)

Upstream product

• 7149-69-1 1,3-dichloro-2-methyl-5-nitrobenzene 
• 54730-35-7 3,5-dichloro-4-methylaniline 
• 204930-37-0 4-bromo-2,6-dichlorotoluene 

Downstream Products

• 274671-77-1 4-bromo-2,6-dichlorobenzyl alcohol 
• 111829-72-2 4-bromo-2,6-dichlorobenzaldehyde 
• 956319-67-8 1-(4-bromo-2,6-dichloro-benzyl)-3-piperidin-1-yl-pyrrolidin-2-one 
• 956123-16-3 2-(4-bromo-2,6-dichloro-benzyl)-2-aza-spiro[4.5]decan-1-one 

Relevant articles and documents

NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS

This invention relates to novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy.

INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1

The present invention discloses novel compounds of Formula I: having 11 Beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11Beta-HSD type 1 activity. X-17377